Pancreatic Cancer Research

ResearcherAsakura Medical Association HospitalActive in the last 2 years

Yasunori Kawaguchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-7756-2462; OpenAlex author ID A5109088658. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 6 papers · 2026: 5 papers

Papers 17

  1. Chemotherapy-induced neutropenia predicts short-term outcome of patients with pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folini… Co-author DOI 10.1002/ijc.70072↗
  2. Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 St… Co-author DOI 10.1111/ajco.70041↗
  3. Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluor… Co-author DOI 10.1177/17588359261442386↗
  4. Effect of biliary drainage and biliary tract infection in unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic ac… Co-author DOI 10.1186/s12885-026-16237-2↗
  5. Dynamic analysis of C-reactive protein/albumin ratio in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-8417823/v1↗
  6. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NA… Co-author DOI 10.1016/j.esmogo.2025.100150↗
  7. Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studie… Co-author DOI 10.1159/000542137↗
  8. Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from … Co-author DOI 10.1177/17588359251320768↗
  9. Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of dat… First author DOI 10.1177/17588359251393156↗
  10. Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results f… Co-author DOI 10.1186/s12885-025-14992-2↗
  11. Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pa… Co-author DOI 10.3389/fonc.2025.1626689↗
  12. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreat… Co-author DOI 10.1038/s41598-024-63172-y↗
  13. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/… Co-author DOI 10.1038/s41598-024-65689-8↗
  14. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retorospective ovservat… Co-author DOI 10.21203/rs.3.rs-3985196/v1↗
  15. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: A multicenter retrospective observati… Co-author DOI 10.21203/rs.3.rs-3677172/v1↗
  16. Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAP… First author DOI 10.1016/j.jgo.2021.06.011↗
  17. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results fr… Co-author DOI 10.1007/s10147-021-01859-2↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junichi Nakazawa · 16 shared papers, 2021–2026 · strength 2.60
  2. Kenji Mitsugi · 16 shared papers, 2021–2026 · strength 2.60
  3. Shiho Arima · 16 shared papers, 2021–2026 · strength 2.60
  4. Futa Koga · 16 shared papers, 2021–2026 · strength 2.60
  5. Mototsugu Shimokawa · 16 shared papers, 2021–2026 · strength 2.60
  6. Taiga Otsuka · 16 shared papers, 2021–2026 · strength 2.60
  7. Tsuyoshi Shirakawa · 16 shared papers, 2021–2026 · strength 2.60
  8. Hiroki Taguchi · 16 shared papers, 2021–2026 · strength 2.60
  9. Kazuo Nishikawa · 14 shared papers, 2023–2026 · strength 2.38
  10. Shuji Arita · 14 shared papers, 2023–2026 · strength 2.38
  11. Taro Shibuki · 12 shared papers, 2021–2026 · strength 1.79
  12. Azusa Komori · 12 shared papers, 2021–2026 · strength 1.79
  13. Keisuke Miwa · 10 shared papers, 2023–2026 · strength 1.58
  14. Yasushi Ide · 8 shared papers, 2021–2026 · strength 1.32
  15. Tomonori Araki · 4 shared papers, 2025–2026 · strength 0.73
  16. Masaru Fukahori · 5 shared papers, 2021–2025 · strength 0.68
  17. Yoshinobu Okabe · 5 shared papers, 2021–2024 · strength 0.64
  18. Akio Ido · 4 shared papers, 2023–2026 · strength 0.60
  19. Norio Ureshino · 4 shared papers, 2021–2025 · strength 0.51
  20. Tomoko Kodama · 3 shared papers, 2023–2024 · strength 0.40
  21. Atsuko Kakihara · 1 shared paper, 2026 · strength 0.20
  22. Wataru Yoshioka · 1 shared paper, 2026 · strength 0.20
  23. Akiko Todaka · 1 shared paper, 2025 · strength 0.17
  24. Tomomi Koike · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.